Endo Int'l (ENDP) Stock Plummets Despite Earnings Beat
NEW YORK (TheStreet) -- Endo International (ENDP) - Get Report stock is down by 14.80% to $51.54 on heavy trading volume on Thursday afternoon, amid a downturn in healthcare stocks today.
The Malvern, PA-based drug company reported earnings before the market open of $1.02 per share. Revenue increased by 14% year over year to $746 million.
Analysts were expecting the company to report earnings of 99 cents per share on revenue of $736 million for the most recent quarter.
Despite Endo's strong earnings report, health care shares were hurt today by a Citron Research report that questioned whether Valeant (VRX)is a "pharmaceutical Enron," the Wall Street Journal reports.
So far today, 15.47 million shares of Endo have exchanged hands versus its 30-day average of 5.89 million shares.
Separately, TheStreet Ratings team rates ENDO INTERNATIONAL PLC as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:
We rate ENDO INTERNATIONAL PLC (ENDP) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and a generally disappointing performance in the stock itself.
You can view the full analysis from the report here: ENDP
data by
Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet or any of its contributors.